Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
Hendrik Schulze-Koops,Klaus Krueger,Inka Vallbracht Vallbracht,Rebecca Hasseli,Alla Skapenko +4 more
Reads0
Chats0
TLDR
Accumulating data suggest that baseline use of bDMARDs is not associated with worse COVID-19 outcome and that some caution may have to be applied when employing rituximab (RTX), a B-cell depleting b DMARD, in patients with immune-mediated disease.Abstract:
It is currently unknown whether immunosuppressive and/or immunomodulating agents such as biological disease-modifying antirheumatic drugs (bDMARDs) affect the rate and the outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections of patients with inflammatory rheumatic diseases (IRDs) While several national authorities have defined patients under immunosuppressive therapy as at risk for severe COVID-19,1 accumulating data from individual cases and also from case series, such as a series from Italy published in the Annals of the Rheumatic Diseases by Monti et al 2 and a report about patients with immune-mediated inflammatory diseases from New York,3 suggest that baseline use of bDMARDs is not associated with worse COVID-19 outcome Although the idea of a potentially protective effect of bDMRADs in COVID-19 is intriguing, we feel that extrapolation of these initial data is dangerous and potentially harmful In particular, some caution may have to be applied when employing rituximab (RTX), a B-cell depleting bDMARD, in patients with immune-mediated disease This notion may be illustrated by the following observations:
We recently lost two patients with rheumatoid arthritis (RA) treated with RTX to lethal COVID-19 The first patient, a 71-year-old man with rheumatoid factor positive, …read more
Citations
More filters
Journal ArticleDOI
Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab.
TL;DR: In this article, the authors report a patient with granulomatosis with polyangiitis (GPA) being treated with rituximab who appears to have developed recurrent SARS-CoV-2 infections in the setting of high-risk employment and on recovery ultimately had no detectable SARS CoV2 IgG antibodies.
Journal ArticleDOI
Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis.
Journal ArticleDOI
Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency – Three consecutive cases and review of the literature
TL;DR: In this paper , the benefits of COVID-19 convalescent plasma (CCP) for patients with humoral immunodeficiency were investigated and a dose from 200 to 800ml was enough in most cases.
Journal ArticleDOI
Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed.
Dimitrios Daoussis,Lydia Leonidou,Christina Kalogeropoulou,Fotini Paliogianni,Argyrios Tzouvelekis +4 more
TL;DR: In this paper, a case of severe, protracted COVID-19 pneumonia in a patient with mixed connective tissue disease (MCTD) who was infected a few days following rituximab (RTX) treatment was presented.
Journal ArticleDOI
B cell depletion impairs vaccination-induced CD8 + T cell responses in a type I interferon-dependent manner.
Theresa Graalmann,Katharina Borst,Himanshu Manchanda,Lea A. I. Vaas,Matthias Bruhn,Lukas Graalmann,Mario Köster,Murielle Verboom,Michael Hallensleben,Carlos A. Guzmán,Gerd Sutter,Reinhold E. Schmidt,Torsten Witte,Ulrich Kalinke +13 more
TL;DR: In this paper, the authors studied CD8+ T cell expansion in rituximab-treated rheumatoid arthritis (RA) patients and B cell-deficient mice on vaccination/infection with different vaccines/pathogens.
References
More filters
Journal ArticleDOI
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
Sara Monti,Silvia Balduzzi,Paolo Delvino,E. Bellis,Verdiana Serena Quadrelli,Carlomaurizio Montecucco +5 more
TL;DR: The survey investigated the patients’ health conditions, the presence of contacts with subjects known to be affected by COVID-19 and management of patients with chronic arthritis treated with biological disease-modifying antirheumatic drugs followed up at the biological outpatient clinic in Pavia, Lombardy.
Journal ArticleDOI
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
Rebecca H. Haberman,Jordan E. Axelrad,Alan Chen,Rochelle Castillo,Di Yan,Peter M. Izmirly,Andrea L. Neimann,Samrachana Adhikari,David Hudesman,Jose U. Scher +9 more
TL;DR: Patients in New York City with known immune-mediated inflammatory disease in whom Covid-19 developed while they were receiving treatment with the drug are described.
Journal ArticleDOI
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia.
Isabella Quinti,Vassilios Lougaris,Cinzia Milito,Francesco Cinetto,Antonio Pecoraro,Ivano Mezzaroma,Claudio Maria Mastroianni,Ombretta Turriziani,Maria Pia Bondioni,Matteo Filippini,Annarosa Soresina,Giuseppe Spadaro,Carlo Agostini,Rita Carsetti,Alessandro Plebani +14 more
TL;DR: In this paper, COVID-19 had a mild clinical course in patients with Agammaglobulinemia lacking B lymphocytes, whereas it developed aggressively in Common Variable Immune Deficiency.
Journal ArticleDOI
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.
Philippe Guilpain,Philippe Guilpain,Clément Le Bihan,Vincent Foulongne,Vincent Foulongne,Patrice Taourel,N. Pansu,Alexandre Thibault Jacques Maria,Alexandre Thibault Jacques Maria,Boris Jung,Romaric Larcher,Kada Klouche,Vincent Le Moing +12 more
TL;DR: The authors rightly recommend a continuous surveillance of patients under immunosuppressants, especially since data are lacking in many systemic autoimmune/inflammatory diseases.
Journal ArticleDOI
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Francis Berenbaum,Francisco J. Blanco,Ali Guermazi,Kenji Miki,Takaharu Yamabe,Lars Viktrup,Rod Junor,William Carey,Mark T. Brown,Christine R. West,Kenneth M. Verburg +10 more
TL;DR: Tanezumab 5 mg statistically significantly improved pain, physical function and PGA-OA, but tanezumsumab 2.5mg only achieved two co-primary end points, but there was a statistically significant improvement in WOMAC Pain and Physical Function, but not PGA -OA.
Related Papers (5)
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Milena A. Gianfrancesco,Kimme L. Hyrich,Sarah Al-Adely,Loreto Carmona,Maria I. Danila,Maria I. Danila,Laure Gossec,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Saskia Lawson-Tovey,Elsa F Mateus,Stephanie Rush,Gabriela Schmajuk,Julia F. Simard,Anja Strangfeld,Laura Trupin,Katherine D Wysham,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Zachary S. Wallace,Jinoos Yazdany,Pedro Machado,Philip Robinson,Philip Robinson +30 more
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Anja Strangfeld,Martin Schäfer,Milena A. Gianfrancesco,Saskia Lawson-Tovey,Jean W. Liew,Lotta Ljung,Elsa F Mateus,Christophe Richez,Maria José Santos,Gabriela Schmajuk,Carlo Alberto Scirè,Emily Sirotich,Jeffrey A. Sparks,Paul Sufka,Thierry Thomas,Laura Trupin,Zachary S. Wallace,Sarah Al-Adely,Javier Bachiller-Corral,Suleman Bhana,Patrice Cacoub,Loreto Carmona,Ruth Costello,Wendy Costello,Laure Gossec,Rebecca Grainger,Eric Hachulla,Rebecca Hasseli,Jonathan S. Hausmann,Kimme L. Hyrich,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Lianne Kearsley-Fleet,Philip Robinson,Philip Robinson,Jinoos Yazdany,Pedro Machado +37 more